Lantheus Stock Forecast, Price & News

Lantheus (NASDAQ:LNTH) Frequently Asked Questions

Is Lantheus a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Lantheus stock.
View analyst ratings for Lantheus or view top-rated stocks.

How has Lantheus' stock been impacted by COVID-19?

Lantheus' stock was trading at $13.62 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LNTH shares have increased by 94.6% and is now trading at $26.50.
View which stocks have been most impacted by COVID-19.

Are investors shorting Lantheus?

Lantheus saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 1,820,000 shares, a decline of 28.9% from the October 31st total of 2,560,000 shares. Based on an average daily trading volume, of 382,700 shares, the days-to-cover ratio is currently 4.8 days. Approximately 2.8% of the shares of the company are sold short.
View Lantheus' Short Interest.

When is Lantheus' next earnings date?

Lantheus is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Lantheus.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) issued its earnings results on Thursday, November, 4th. The medical equipment provider reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. The medical equipment provider earned $102.10 million during the quarter, compared to analyst estimates of $97.13 million. Lantheus had a negative net margin of 8.84% and a positive trailing twelve-month return on equity of 4.17%. The company's revenue was up 15.4% compared to the same quarter last year. During the same period last year, the firm posted $0.04 EPS.
View Lantheus' earnings history.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus issued an update on its FY 2021 earnings guidance on Thursday, November, 25th. The company provided EPS guidance of $0.400-$0.430 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.390. The company issued revenue guidance of $405 million-$410 million, compared to the consensus revenue estimate of $396.70 million.

What price target have analysts set for LNTH?

2 brokers have issued 1-year price objectives for Lantheus' shares. Their forecasts range from $20.00 to $34.00. On average, they expect Lantheus' stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 1.9% from the stock's current price.
View analysts' price targets for Lantheus or view top-rated stocks among Wall Street analysts.

Who are Lantheus' key executives?

Lantheus' management team includes the following people:

• Mary Anne Heino, President, Chief Executive Officer & Director (LinkedIn Profile)
• Robert J. Marshall, Chief Financial Officer & Treasurer
• Simon Robinson, Senior VP-Research & Pharmaceutical Development
• Iryna Teslenko, Vice President-Clinical Development
• Bela S. Denes, Vice President-Medical Affairs

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus CEO Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among Lantheus' employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Lantheus' key competitors?

Some companies that are related to Lantheus include Quidel (QDEL), Neogen (NEOG), Ortho Clinical Diagnostics (OCDX), Myriad Genetics (MYGN), Heska (HSKA), Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Alpha Teknova (TKNO), Lucira Health (LHDX), MyMD Pharmaceuticals (MYMD), Quotient (QTNT), OncoCyte (OCX), Aspira Women's Health (AWH), VolitionRx (VNRX) and Nymox Pharmaceutical (NYMX).
View all of LNTH's competitors.

What other stocks do shareholders of Lantheus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO).

When did Lantheus IPO?

(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.56%), Wellington Management Group LLP (7.00%), Thrivent Financial for Lutherans (4.40%), William Blair Investment Management LLC (3.89%), Artisan Partners Limited Partnership (3.19%) and Dimensional Fund Advisors LP (2.50%). Company insiders that own Lantheus stock include Andrea Sabens, Etienne Montagut, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends for Lantheus.

Which major investors are selling Lantheus stock?

LNTH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Russell Investments Group Ltd., BlackRock Inc., Pura Vida Investments LLC, Peregrine Capital Management LLC, Boston Partners, MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income, and Tamarack Advisers LP. Company insiders that have sold Lantheus company stock in the last year include Andrea Sabens, Etienne Montagut, John J Bolla, Mary Anne Heino, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall, and Sam R Leno.
View insider buying and selling activity for Lantheus or view top insider-selling stocks.

Which major investors are buying Lantheus stock?

LNTH stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Polar Asset Management Partners Inc., Thrivent Financial for Lutherans, Fisher Asset Management LLC, Arrowstreet Capital Limited Partnership, The Manufacturers Life Insurance Company , Next Century Growth Investors LLC, and Royal Bank of Canada.
View insider buying and selling activity for Lantheus or or view top insider-buying stocks.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $26.50.

How much money does Lantheus make?

Lantheus has a market capitalization of $1.79 billion and generates $339.41 million in revenue each year. The medical equipment provider earns $-13.47 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does Lantheus have?

Lantheus employs 595 workers across the globe.

What is Lantheus' official website?

The official website for Lantheus is www.lantheus.com.

Where are Lantheus' headquarters?

Lantheus is headquartered at 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at (978) 671-8001, via email at [email protected], or via fax at 978-671-8860.